Catecholaminergic polymorphic ventricular tachycardia [Katecholaminerge polymorphe ventrikuläre Tachykardien]

被引:2
|
作者
Frommeyer G. [1 ]
Pott C. [1 ]
Eckardt L. [1 ]
Schulze-Bahr E. [2 ]
机构
[1] Abteilung Fur Rhythmologie, Department Fur Kardiologie und Angiologie, Universitatsklinikum Munster
[2] Institut Fur Genetik von Herzerkrankungen (IfGH), Department Fur Kardiologie und Angiologie, Universitatsklinikum Munster
关键词
A-Blocker therapy; Catecholaminergic polymorphic ventricular tachycardia; Flecainide; Implantable cardioverter-defibrillator; Sudden cardiac death;
D O I
10.1007/s00399-012-0224-8
中图分类号
学科分类号
摘要
Catecholaminergic polymorphic ventricular tachycardia (PCVT) is a rare, congenital ventricular tachyarrhythmia which occurs in the setting of adrenergic activation. It potentially leads to syncope and/or sudden cardiac death (SCD). PCVT represents one of the most dangerous congenital ion channel diseases. Mutations of the ryanodine receptor gene (RYR2), the calsequestrin gene (CASQ2), and the triadin gene (TRDN) have been identified as an underlying correlate. a-Blockers are employed as therapy and are sometimes combined with class IC antiarrhythmic drugs, or calcium antagonists of the verapamil type. ICD implantation is recommended in case of persisting syncope in the presence of a-blocker therapy or survived SCD. Left thoracic sympathectomy represents a subsidiary interventional therapy for individual cases. In addition, modifications of the patient"s lifestyle including avoidance of physical stress and heart rates > 120/min are recommended. © Springer-Verlag 2012.
引用
收藏
页码:231 / 236
页数:5
相关论文
共 50 条
  • [31] Catecholaminergic Polymorphic Ventricular Tachycardia with QT Prolongation
    Tanaka, Yasuaki
    Kawabata, Mihoko
    Scheinman, Melvin M.
    Hirao, Kenzo
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2015, 38 (12): : 1499 - 1502
  • [32] Molecular basis of catecholaminergic polymorphic ventricular tachycardia
    Gyoerke, Sandor
    HEART RHYTHM, 2009, 6 (01) : 123 - 129
  • [33] Anesthesia for a patient with catecholaminergic polymorphic ventricular tachycardia
    Dornan, RIP
    ANESTHESIA AND ANALGESIA, 2002, 95 (03): : 555 - 557
  • [34] Current topics in catecholaminergic polymorphic ventricular tachycardia
    Sumitomo, Naokata
    JOURNAL OF ARRHYTHMIA, 2016, 32 (05) : 344 - 351
  • [35] Catecholaminergic polymorphic ventricular tachycardia: a current overview
    Leite, Luiz R.
    Henz, Benhur D.
    Macedo, Paula G.
    Santos, Simone N.
    Barreto, Jose R.
    Zanatta, Andre
    Fenelon, Guilherme
    Cruz Filho, Fernando E. S.
    FUTURE CARDIOLOGY, 2009, 5 (02) : 191 - 199
  • [36] Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia
    Imberti, Jacopo F.
    Underwood, Katherine
    Mazzanti, Andrea
    Priori, Silvia G.
    HEART LUNG AND CIRCULATION, 2016, 25 (08): : 777 - 783
  • [37] Arrhythmogenic Mechanism of Catecholaminergic Polymorphic Ventricular Tachycardia
    Liu, Nian
    Colombi, Barbara
    Priori, Silvia G.
    JOURNAL OF ARRHYTHMIA, 2006, 22 (04) : 202 - 208
  • [38] Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia
    Priori, Silvia G.
    Mazzanti, Andrea
    Santiago, Demetrio J.
    Kukavica, Deni
    Trancuccio, Alessandro
    Kovacic, Jason C.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (20) : 2592 - 2612
  • [39] Calsequestrin Mutations and Catecholaminergic Polymorphic Ventricular Tachycardia
    Faggioni, Michela
    Kryshtal, Dmytro O.
    Knollmann, Bjorn C.
    PEDIATRIC CARDIOLOGY, 2012, 33 (06) : 959 - 967
  • [40] Calsequestrin Mutations and Catecholaminergic Polymorphic Ventricular Tachycardia
    Michela Faggioni
    Dmytro O. Kryshtal
    Björn C. Knollmann
    Pediatric Cardiology, 2012, 33 : 959 - 967